The Indian Supreme Court's decision in a case involving Novartis' cancer drug Glivec is expected Monday, and it could have extensive consequences for branded drugs in the nation. "With this verdict, at least, things will get clearer about what is the definition of patented medicines," said Ajay Kumar Sharma of consultant Frost & Sullivan. India has cited affordability in almost all patent disputes as a major reason to let generic-drug makers release copies of patented treatments.

Full Story:

Related Summaries